Newsletters

[Journal of Cell Science] Researchers investigated the role of SNED1–integrin interactions in SNED1 ECM assembly. They found that the LDV motif, but not the RGE motif, in SNED1, was required for ECM build-up and the patterning of SNED1 and the fibrillar proteins fibronectin and collagen.

[Stemora, Inc. (BioBuzz)] Stemora, Inc. announced that it has received a $100,000 matching grant from the Maryland Industrial Partnerships program to fund a collaboration with Dr. Srinivasa Raghavan at the University of Maryland. The project will engineer controlled-release hydrogel formulations for STM-01.

[UCD School of Medicine ] The European Research Council has announced the winners of its latest Starting Grant competition. Drs. Seungkuk Ahn and Dr Alan Seltzer, have received a total of almost €4 million in funding to help build their own teams and develop their research.

[Trends in Cancer] Scientists synthesize evidence that tumors become locked in either proinflammatory or pro-resolution phases, defined by neutrophil- or macrophage-dominated ecosystems.

[Cell Biomaterials] The authors summarize recent advances in recapitulating the ECM in organ-on-chip systems and argue that the next generation of organ-on-chip platforms will be defined not by increasing structural complexity alone but by their ability to integrate biologically instructive ECMs with manufacturable biomaterial systems.

[iScience] Researchers developed degradable amorphous silica fiber scaffolds that actively support biomineral nucleation and growth while maintaining long-term stability. The scaffolds degraded linearly over 40 weeks, and biomineralization enhanced compressive modulus by more than 100%.

[Cancer Research] Challenging the prevailing fibroblast-centric paradigm, investigators provide an overview of how non-fibroblast cell types engage in dynamic crosstalk and collectively shape the biochemical and biomechanical landscape of tumors.

[Journal of Histochemistry & Cytochemistry] Scientists evaluated ECM alterations in a rat model of Peyronie’s disease induced by transforming growth factor beta and to assess the potential antifibrotic effects of mycophenolate mofetil.

[Proceedings of the National Academy of Sciences of the United States of America] Investigators identified a previously unrecognized RNA-based mechanism that maintains pathogenic fibroblast states during skin fibrosis.

[Clinical and Translational Medicine] The authors employed cellular and in vivo animal models to validate the effects of the TRIM25-USP7-ENO1 axis on glycolysis, mitochondrial function, ATP levels, and ECM degradation.

[Experimental & Molecular Medicine] Researchers analyzed protein kinase Cδ (PKCδ) expression in human atheroma datas and investigated its role using low-density lipoprotein receptor-knockout mice with global and myeloid-specific PKCδ deletion.

[Aptar Pharma] Aptar Pharma, a global leader in drug delivery, announced a collaboration with Aceso Therapeutics, a biotech developing novel therapies for cystic fibrosis to advance the development of ACT-101, designed to target the underlying disease mechanisms.